Form 4: Klamkin Sells Aeluma Shares Under 10b5-1 Plan

Jonathan Klamkin, CEO and Director of Aeluma, Inc., reported the sale of 20,000 common shares for approximately $261,940 under a pre-established Rule 10b5-1 trading plan.

Summary

• Jonathan Klamkin, who holds the positions of Chief Executive Officer and Director at Aeluma, Inc., has reported a transaction involving the sale of 20,000 shares of common stock.
• The sale occurred on April 1, 2026, and was executed under a Rule 10b5-1 trading plan that was adopted on December 3, 2025.
• The weighted average sale price for these shares was $13.0975, with individual transaction prices ranging from $12.82 to $13.325.
• Following this transaction, Klamkin beneficially owns 1,409,398 shares of Aeluma, Inc. common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative event. While the sale is conducted under a Rule 10b5-1 plan, which is designed to avoid insider trading implications, any sale by a CEO can be perceived negatively by the market.

Negatives

• Sale of a significant number of shares (20,000) by a key executive (CEO and Director).

Risks

• The sale of shares by a CEO and Director could be interpreted by the market as a lack of confidence in the company's future prospects, potentially impacting investor sentiment.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The transaction was executed under a pre-determined trading plan.

Management Comments

• The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions. The use of a Rule 10b5-1 plan is a common strategy for executives to sell shares without triggering insider trading concerns, as it establishes a pre-arranged plan for sales at a predetermined time or price, or based on a formula. However, the market often scrutinizes sales by top executives, regardless of the plan's structure.

Stakeholder Impact

• Shareholders: May view the sale by the CEO with caution, potentially leading to short-term negative sentiment or a decrease in share price, despite the Rule 10b5-1 plan.
• Employees: May also interpret the sale as a sign of reduced confidence from leadership, potentially affecting morale.
• Creditors/Suppliers: Unlikely to be directly impacted by this specific transaction.

Next Steps

• The reporting person has committed to providing detailed information on individual sale prices upon request from regulatory bodies, the issuer, or security holders.

Key Dates

Recommendation

The filing reports a routine sale of shares by the CEO under a Rule 10b5-1 plan. While insider sales can be a negative signal, the structured nature of the sale mitigates concerns about immediate insider knowledge. The company's overall financial health and future prospects, not detailed in this Form 4, would be the primary drivers for a buy or sell recommendation. Therefore, a 'hold' position is appropriate pending further information.

Keywords

Aeluma Inc, ALMU, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Jonathan Klamkin, CEO, Director, Beneficial Ownership